Skip to main content
. 2018 Mar 9;97(10):e0097. doi: 10.1097/MD.0000000000010097

Table 2.

Treatment effects within subgroups defined by primary tumor location (PTL) in patients with RAS wild-type metastatic colorectal cancer.

3.1.